Wockhardt Exits US Generics, Focuses on Antibiotics and Insulin

Wockhardt exits loss-making US generics business, shifts focus to drug discovery and insulin portfolios, aiming to improve profits and target emerging markets.

Cipla Receives Approval for Inhaled Insulin in India

Cipla's approval for distribution of Afrezza inhalation human insulin in India offers a rapid-acting, non-injectable insulin option for diabetes patients.